Mohamad Hussein

Summary

Affiliation: Celgene Corporation
Country: USA

Publications

  1. pmc Vorinostat in solid and hematologic malignancies
    David Siegel
    Hackensack University Medical Center, Hackensack, NJ, USA
    J Hematol Oncol 2:31. 2009
  2. pmc A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
    Mohamad Hussein
    The Cleveland Clinic Foundation, Cleveland, OH, USA
    Haematologica 95:845-8. 2010
  3. doi request reprint Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen
    Todd W Kelley
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44120, USA
    Hum Pathol 40:405-12. 2009
  4. ncbi request reprint Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma
    Rachid Baz
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    Leuk Lymphoma 48:2338-44. 2007
  5. ncbi request reprint The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma
    Rony M Abou-Jawde
    Myeloma Research Program, Cleveland Clinic, Cleveland, Ohio, USA
    Haematologica 91:1410-3. 2006
  6. doi request reprint A review of the history, properties, and use of the immunomodulatory compound lenalidomide
    Jerome B Zeldis
    Celgene Corporation, Summit, New Jersey, USA
    Ann N Y Acad Sci 1222:76-82. 2011
  7. doi request reprint CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
    Eric D Hsi
    Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Cancer Res 14:2775-84. 2008
  8. ncbi request reprint Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial
    Rony M Abou-Jawde
    Department of Hematology and Medical Oncology, Multiple Myeloma Program, Cleveland, OH 44195, USA
    Med Oncol 23:263-72. 2006
  9. ncbi request reprint Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival
    James R Cook
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Clin Pathol 125:615-24. 2006
  10. ncbi request reprint Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer
    Navneet S Majhail
    Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
    Invest New Drugs 22:421-6. 2004

Collaborators

Detail Information

Publications10

  1. pmc Vorinostat in solid and hematologic malignancies
    David Siegel
    Hackensack University Medical Center, Hackensack, NJ, USA
    J Hematol Oncol 2:31. 2009
    ....
  2. pmc A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
    Mohamad Hussein
    The Cleveland Clinic Foundation, Cleveland, OH, USA
    Haematologica 95:845-8. 2010
    ..The observed safety profile suggested that dacetuzumab may be combined with other multiple myeloma therapies. Two combination trials are ongoing. Clinical trials gov identifier: NCT00079716...
  3. doi request reprint Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen
    Todd W Kelley
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44120, USA
    Hum Pathol 40:405-12. 2009
    ..The findings suggest that a thalidomide-based regimen may overcome the poor prognosis associated with a cyclin D1-negative or fibroblast growth factor receptor 3-positive phenotype...
  4. ncbi request reprint Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma
    Rachid Baz
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    Leuk Lymphoma 48:2338-44. 2007
    ..The toxicity of the combination was overall manageable and consistent with what is generally noted with MP chemotherapy. The combination of rituximab to MP therapy did not result in improved response rate or event-free survival...
  5. ncbi request reprint The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma
    Rony M Abou-Jawde
    Myeloma Research Program, Cleveland Clinic, Cleveland, Ohio, USA
    Haematologica 91:1410-3. 2006
    ..In conclusion, socioeconomic status, distance traveled and race did not affect outcomes of MM patients treated at a specialized myeloma center...
  6. doi request reprint A review of the history, properties, and use of the immunomodulatory compound lenalidomide
    Jerome B Zeldis
    Celgene Corporation, Summit, New Jersey, USA
    Ann N Y Acad Sci 1222:76-82. 2011
    ..Several early-stage studies are exploring lenalidomide alone and in combination across different hematological malignancies, solid tumors, and immune-related disorders...
  7. doi request reprint CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
    Eric D Hsi
    Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Cancer Res 14:2775-84. 2008
    ....
  8. ncbi request reprint Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial
    Rony M Abou-Jawde
    Department of Hematology and Medical Oncology, Multiple Myeloma Program, Cleveland, OH 44195, USA
    Med Oncol 23:263-72. 2006
    ..Because preclinical data suggested greater activity with dexamethasone and ascorbic acid, a phase 2 trial of the combination of arsenic trioxide, dexamethasone, and ascorbic acid in patients with relapsed or refractory MM was conducted...
  9. ncbi request reprint Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival
    James R Cook
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Clin Pathol 125:615-24. 2006
    ..005). This report shows for the first time that cyclin D1 immunohistochemical analysis can provide prognostic information in plasma cell myeloma...
  10. ncbi request reprint Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer
    Navneet S Majhail
    Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
    Invest New Drugs 22:421-6. 2004
    ....